Table of contents

Clinical/translational cancer immunotherapy

• Ipilimumab plus nivolumab in avelumab-refractory Merkel cell carcinoma: a multicenter study of the prospective skin cancer registry ADOREG (30 November, 2022)

  Valerie Glutsch, Patrick Schummer, Hermann Kneitz, Anja Gesierich, Matthias Goebeler, Detlef Klein, Christian Posch, Christoffer Gebhardt, Sebastian Haferkamp, Lisa Zimmer, Jürgen C Becker, Ulrike Leiter, Michael Weichenthal, Dirk Schadendorf, Selma Ugurel, Bastian Schilling
• Original research: Immune checkpoint inhibitor therapy and outcomes from SARS-CoV-2 infection in patients with cancer: a joint analysis of OnCovid and ESMO-CoCARE registries (30 November, 2022)

  Alessio Cortellini, Gino M Dettorre, Urania Dafni, Juan Aguilar-Company, Luis Castelo-Branco, Matteo Lambertini, Spyridon Gennatas, Vasileios Angelis, Ailsa Sita-Lumsden, Jacobo Rogado, Paolo Pedrazzoli, David Viñal, Aleix Prat, Maura Rossi, Rossana Berardi, Teresa Alonso-Gordoa, Salvatore Grisanti, Georgia Dimopoulou, Paola Queirolo, Sylvain Pradervand, Alexia Bertuzzi, Mark Bower, Dirk Arnold, Ramon Salazar, Marco Tucci, Kevin J Harrington, Francesca Mazzoni, Uma Mukherjee, Zoi Tsourti, Olivier Michielin, Fanny Pommeret, Joan Brunet, Bruno Vincenzi, Giuseppe Tonini, Andrea Patriarca, Federica Biello, Marco Krengli, Josep Tabernero, George Pentheroudakis, Alessandra Gennari, Solange Peters, Emanuela Romano, David J Pinato
• Original research: Phase II clinical and immune correlate study of adjuvant nivolumab plus ipilimumab for high-risk resected melanoma (30 November, 2022)

  Nikhil I Khushalani, Melinda Vassallo, Judith D Goldberg, Zeynep Eroglu, Younchul Kim, Biwei Cao, Robert Ferguson, Kelsey R Monson, Tomas Kirchhoff, Carol M Amato, Paulo Burke, Ann Strange, Emily Monk, Geoffrey Thomas Gibney, Ragini Kudchadkar, Joseph Markowitz, Andrew S Brohl, Anna Pavlick, Alison Richards, David M Woods, Jeffrey Weber
• Original research: Nivolumab after selective internal radiation therapy for the treatment of hepatocellular carcinoma: a phase 2, single-arm study (30 November, 2022)

  Manuel de la Torre-Aláez, Ana Matilla, Maria Varela, Mercedes Iñarrairaegui, Maria Reig, Jose Luis Lledó, Juan Ignacio Arenas, Sara Lorente, Milagros Testillano, Laura Márquez, Leonardo Da Fonseca, Josepmaria Argemí, Carlos Gómez-Martin, Macarena Rodriguez-Fraile, Jose I Bilbao, Bruno Sangro
• Original research: Patient-derived Siglec-6-targeting antibodies engineered for T-cell recruitment have potential therapeutic utility in chronic lymphocytic leukemia (28 November, 2022)

  Matthew G Cyr, Maissa Mhibik, Junpeng Qi, Haiyong Peng, Jing Chang, Erika M Gaglione, David Eik, John Herrick, Thomas Venables, Scott J Novick, Valentine V Courouble, Patrick R Griffin, Adrian Wiestner, Christoph Rader
• Original research: Inhibiting DNA methylation and RNA editing upregulates immunogenic RNA to transform the tumor microenvironment and prolong survival in ovarian cancer (7 November, 2022)

  Stephanie Gomez, Olivia L Cox, Reddick R Walker, Uzma Rentia, Melissa Hadley, Elisa Arthofer, Noor Diab, Erin E Grundy, Tomas Kanholm, James I McDonald, Julie Kobyra, Erica Palmer, Satish Noonepalle, Alejandro Villagra, David Leitenberg, Catherine M Bollard, Yogen Saunthararajah, Katherine B Chiappinelli
• FRACTION-RCC: nivolumab plus ipilimumab for advanced renal cell carcinoma after progression on immuno-oncology therapy (3 November, 2022)

  Toni K Choueiri, Harriet Kluger, Saby George, Scott S Tykodi, Timothy M Kuzel, Ruth Perets, Suresh Nair, Giuseppe Procopio, Michael A Carducci, Vincent Castonguay, Edmund Folefac, Chung-Han Lee, Sebastien J. Hotte, Wilson H Miller,, Shruti Shally Saggi, Chung-Wei Lee, Heshani Desilva, Prabhu Bhagavatheeswaran, Robert J Motzer, Bernard Escudier
• Original research: Metformin increases natural killer cell functions in head and neck squamous cell carcinoma through CXCL1 inhibition (3 November, 2022)

  McKenzie Crist, Benyamin Yaniv, Sarah Palackdharry, Maria A Lehn, Mario Medvedovic, Timothy Stone, Shuchi Gulati, Vidhya Karivedu, Michael Borchers, Bethany Fuhrman, Audrey Crago, Joseph Curry, Ubaldo Martinez-Outschoorn, Vinita Takiar, Trisha M Wise-Draper
• Original research: Deciphering molecular and cellular ex vivo responses to bispecific antibodies PD1-TIM3 and PD1-LAG3 in human tumors (1 November, 2022)

  Marina Natoli, Klas Hatje, Pratiksha Gulati, Fabian Junker, Petra Herzig, Zhiwen Jiang, Iakov I Davydov, Markus Germann, Marta Trüb, Daniel Marbach, Adrian Zwick, Patrick Weber, Stefan Seeber, Mark Wiese, Didier Lardinois, Viola Heinzelmann-Schwarz, Robert Rosenberg, Lothar Tietze, Kirsten D Mertz, Pablo Umaña, Christian Klein, Laura Codarri-Deak, Henry Kao, Alfred Zippelius
• Original research: Bispecific antibodies targeting CD40 and tumor-associated antigens promote cross-priming of T cells resulting in an antitumor response superior to monospecific antibodies (2 November, 2022)

  Karin Hägerbrand, Laura Varas, Adnan Deronic, Barnabas Nyesiga, Anette Sundstedt, Lill Ljung, Christina Sakellariou, Doreen Werchau, Mia Thagesson, David Gomez Jimenez, Lennart Greiff, Mona Celander, Kristine Smedenfors, Anna Rosén, Deniz Bölükbas, Fredrika Carlsson, Mattias Levin, Anna Säll, Laura von Schantz, Malin Lindstedt, Peter Ellmark